Matrajt L, Janes H, Schiffer JT and Dimitrov D. Quantifying the impact of lifting community non-pharmaceutical interventions for COVID-19 during vaccination rollout in the United States. Submitted.

Matrajt L, Eaton J, Leung T, Dimitrov D, Schiffer JT, Swan DA and Janes H. Optimizing vaccine allocation for COVID-19 vaccines: potential role of single-dose vaccination. Submitted. 10.1101/2020.12.31.20249099v2

Swan DA, Bracis C, Janes H, Moore M, Matrajt L, et al. COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact. Submitted,

Matrajt L, Eaton J, Leung T and Brown ER. Vaccine optimization for COVID-19: who to vaccinate first? Science Advances, 2021.

Matrajt L and Leung T. Evaluating the Effectiveness of Social Distancing Interventions to Delay or Flatten the Epidemic Curve of Coronavirus Disease. Emerging Infectious Diseases, 2020.

Leung T and Matrajt L. Protection afforded by previous Vibrio cholerae infection against subsequent disease and infection: a review. Accepted, PLoS Neglected Tropical Diseases.

Lee EC, Chao DL, Lemaitre JC, Matrajt L et al. Achieving coordinated national immunity and cholera elimination in Haiti through vaccination: a modelling study. The Lancet Global Health, 2020.

Matrajt L, Halloran ME, Antia R. Successes and failures of the live-attenuated influenza vaccine, can we do better? Clinical Infectious Diseases, 2019. 1093/cid/ciz358/5485903

Matrajt L, Gantt S, Mayer BT, Krantz EM, Orem J, Wald A, Corey L, Schiffer JT, Casper C. Virus and host-specific differences in oral human herpesvirus shedding kinetics among Ugandan women and children. Nature Scientific Re- ports, 2017, Oct 12;7(1):13105.

Mayer BT, Matrajt L, Casper C, Krantz EM, Corey L, Wald A, Gantt S, Schiffer JT. Dynamics of Persistent Oral Cytomegalovirus Shedding During Primary Infection in Ugandan Infants Journal of Infectious Diseases, 2016 Dec 1;214(11):1735-174

Feldstein LR, Matrajt L, Halloran ME, Keitel WA, Longini IM Jr., H5N1 Vaccine Working Group. Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies. Vaccine, 2016 Jul 19;34(33):3796-802

Matrajt L, Britton T, Halloran ME, and Longini IM Jr. One versus two doses: what is the best use of vaccine in an influenza pandemic? Epidemics Dec. 2015.

Matrajt L, Younan PM, Kiem HP, Schiffer JT. The majority of CD4+ T-cell depletion during acute SHIV89.6P in- fection occurs in uninfected cells, Journal of Virology, 2014 Mar;88(6):3202-12.

Matrajt L, Halloran ME, and Longini IM Jr. Optimal vaccine allocation for the early mitigation of pandemic influen- za, PLoS Computational Biology, 2013, 9(3): e1002964.

Matrajt L and Longini IM Jr. Critical immune and vaccination thresholds for determining multiple influenza epide- mic waves, Epidemics, Volume 4, Issue 1, March 2012, Pages 22-32, ISSN 1755-4365, 10.1016/j.epidem.2011.11.003.

Kenah E, Chao DL, Matrajt L, Halloran ME, Longini IM Jr. The Global Transmission and Control of Influenza. PLoS ONE. 2011; 6(5): e19515.

Chao DL, Matrajt L, Basta NE, Sugimoto JD, Dean B, Bagwell DA, Oiulfstad B, Halloran ME, Longini IM Jr. Planning control of pandemic influenza H1N1 in Los Angeles County and the US, American Journal of Epidemiology. 2011; 173 (10): 1121-1130.

Matrajt L, Longini IM Jr. Optimizing Vaccine Allocation at Different Points in Time during an Epidemic. PLoS ONE. 2010; 5(11): e13767. doi:10.1371/journal.pone.0013767

Yang Y, Sugimoto JD, Halloran ME, Basta NE, Chao DL, Matrajt L, Potter G, Kenah E, Longini Jr. IM. The Transmissibility and Control of Pandemic Influenza A (H1N1) Virus. Science. 2009: 729-733.

Basta NE, Chao DL, Halloran ME, Matrajt L, Longini IM Jr.Strategies for Influenza Vaccination of School Children in the US. American Journal of Epidemiology. 2009; 170: 679-686.

Basta NE, Halloran ME, Matrajt L, Longini IM Jr. Estimating Influenza Vaccine Efficacy From Challenge and Community-based Study Data. American Journal of Epidemiology. 2008; 168(12):1343-52